NEWSROOM

Stay current with MiRXES

Newsroom > Media Releases

Mirxes secures $40m to expand cancer diagnostics in Asia

Singapore, 13 January 2025 – Singapore-based RNA technology firm Mirxes has secured US$40 million in structured financing from CBC Group’s R-Bridge Healthcare Fund.

The funding will help the company expand globally, focusing on high-growth markets in the Asia-Pacific region, including Southeast Asia, China, and Japan.

R-Bridge, which is Asia’s first healthcare-focused structured financing fund, provides solutions for life sciences companies backed by royalties and cash flows.

This synthetic royalty-backed transaction will enable Mirxes to advance its RNA diagnostic technologies and meet its strategic priorities.

Mirxes specializes in cancer early detection and produces GastroClear, a non-invasive blood-based diagnostic test for gastric cancer.

It is the first In Vitro Diagnostics product to receive regulatory approval in this category worldwide.

About Mirxes

Mirxes is a leading RNA technology company that is making cancer early detection solutions accessible on a global scale. Leading the global fight against cancer, our flagship initiative, Project CADENCE (Cancer Detected Early caN be CurEd), leverages our industry-leading RNA technology platform, deep expertise in PCR diagnostics, and population-scale next-generation sequencing (NGS) capabilities to create a blood-based multi-cancer early detection test to alleviate cancer burden, save lives and reduce healthcare costs. Founded in 2014, Mirxes is a high growth company, headquartered in Singapore, producing diagnostic test kits for early disease detection globally, and delivering research and clinical testing services for preventive healthcare and precision medicine to key markets in Asia and beyond. For more information, visit https://mirxes.com/. Follow us on LinkedIn, Facebook and Instagram.

Scroll to Top